ATS GUIDELINES Bundle

Nucleic Acid-Based Testing in Community Acquired Pneumonia

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/1364269

Contents of this Issue

Navigation

Page 1 of 3

Key Points ➤ There is increasing recognition that respiratory viruses are frequent causative agents of community acquired pneumonia (CAP). ➤ Although at the time of document development SARS-CoV-2 was not a recognized CAP-causing pathogen, nucleic acid amplification tests (NAATs) are the cornerstone of the CDC's United States SARS-CoV-2 Surveillance Plan. ➤ In outpatients with suspected CAP, the ATS suggests not performing routine nucleic acid-based testing of respiratory samples for viral pathogens other than influenza. (C-VL) ➤ In hospitalized patients with suspected CAP, the ATS suggests nucleic acid-based testing of respiratory samples for viral pathogens other than influenza only in patients that meet one of the following conditions (C-VL): • Patients with severe CAP (i.e., patients with ≥1 major or ≥3 minor criteria) • Immunocompromised patients (including neutropenia, active cancer therapy, history of solid organ or blood component transplant, advanced HIV disease, or chronic use of immunosuppressive medications including systemic corticosteroids). Diagnosis

Articles in this issue

view archives of ATS GUIDELINES Bundle - Nucleic Acid-Based Testing in Community Acquired Pneumonia